VERU Stock Analysis: Buy, Sell, or Hold?
VERU - Veru Inc.
$2.25
-0.10 (-4.26%)
▼
5d:
-3.43%
30d:
+0.0%
90d:
-10.36%
BUY
HIGH Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When VERU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: VERU shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: VERU shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: VERU is currently trading at $2.25, which is considered fair relative to its 30-day fair value range of $2.17 to $2.33.
Technical Outlook: Technically, VERU is in a downtrend. Immediate support is located at $2.07, while resistance sits at $2.40. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: VERU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.50 (+988.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VERU is in a downtrend. Immediate support is located at $2.07, while resistance sits at $2.40. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: VERU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.50 (+988.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.17 -
$2.33
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 988.9% below Wall St target ($24.50)
Trading Range Analysis
30-Day Trading Range
$2.17 -
$2.33
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.36
(15.8%)
Support & Resistance Levels
Support Level
$2.07
Resistance Level
$2.40
Current Trend
Downtrend
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.28
Wall Street Target
$24.50
(+988.9%)
Revenue Growth (YoY)
18.3%
Share & Embed Analysis
Last updated: June 03, 2026 6:04 PM ET
Data refreshes hourly during market hours. Next update: 7:04 PM
Data refreshes hourly during market hours. Next update: 7:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 55 HOLD |
